Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof
AssigneesMerck Sharp & Dohme Corp., Eisai R&D Management Co., Ltd.
InventorsRachel A. Altura, Philip E. Brandish, Rodolfo Fleury Perini
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating cancer (e.g., RCC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) lenvatinib represented by Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.
Claims33
A method of treating cancer, comprising administering to a human patient in need thereof:
- (a) a PD-1 antagonist;
- (b) an ILT4 antagonist;
- and
- (c) lenvatinib represented by Formula (I),
- or a pharmaceutically acceptable salt thereof.
4-12. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating RCC, comprising administering to a human patient in need thereof:
- (a) 200 mg pembrolizumab;
- (b) 800 mg of an anti-human ILT4 monoclonal antibody or antigen binding fragment thereof that comprises a VL CDR1, a VL CDR2, and a VL CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:1, 2, and 3, respectively, and a VH CDR1, a VH CDR2, and a VH CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:6, 7, and 8, respectively;
- and
- (c) 20 mg lenvatinib.
(canceled)
Dependencies are inferred from the claim text.